ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Lantern Pharma Inc

Lantern Pharma Inc (LTRN)

3.35
-0.15
(-4.29%)
At close: September 10 4:00PM
3.35
0.00
( 0.00% )
After Hours: 4:17PM

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
3.35
Bid
3.26
Ask
3.43
Volume
30,964
3.262 Day's Range 3.49
2.38 52 Week Range 11.99
Market Cap
Previous Close
3.50
Open
3.49
Last Trade
1
@
3.43
Last Trade Time
17:29:36
Financial Volume
$ 105,199
VWAP
3.3975
Average Volume (3m)
58,046
Shares Outstanding
10,764,725
Dividend Yield
-
PE Ratio
-2.26
Earnings Per Share (EPS)
-1.48
Revenue
-
Net Profit
-15.96M

About Lantern Pharma Inc

Lantern Pharma Inc is a clinical-stage biotechnology company. It is focused on leveraging artificial intelligence (A.I), machine learning and genomic data to streamline the drug development process and to identify the patients that will benefit from targeted oncology therapies. The firm's pipeline o... Lantern Pharma Inc is a clinical-stage biotechnology company. It is focused on leveraging artificial intelligence (A.I), machine learning and genomic data to streamline the drug development process and to identify the patients that will benefit from targeted oncology therapies. The firm's pipeline of development programs involves four drug candidates and an Antibody Drug Conjugate (ADC) program directed towards eight therapeutic targets. Its A.I. platform, known as RADR, includes more than 18 billion data points, and uses big data analytics and machine learning to rapidly uncover biologically relevant genomic signatures correlated to drug response, and then identify the cancer patients that we believe may benefit most from our compounds. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
-
Lantern Pharma Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker LTRN. The last closing price for Lantern Pharma was $3.50. Over the last year, Lantern Pharma shares have traded in a share price range of $ 2.38 to $ 11.99.

Lantern Pharma currently has 10,764,725 shares outstanding. The market capitalization of Lantern Pharma is $37.68 million. Lantern Pharma has a price to earnings ratio (PE ratio) of -2.26.

LTRN Latest News

Lantern Pharma Reports Second Quarter 2024 Financial Results and Business Updates

Active clinical trials across three AI-guided drug candidates with additional ADC-based preclinical molecules in evaluation for development. Preliminary patient data and clinical readouts for...

 Lantern Pharma Highlights Promising Preclinical Results of LP-184’s Synergy with Checkpoint Inhibitors & Sensitizing Tumors That are Non-Responsive to Anti-PD1 Therapy in Collaboration with MD Anderson at Immuno-Oncology Summit 2024

Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging artificial intelligence (AI) and machine learning to transform the cost, pace, and timeline of oncology drug...

Lantern Pharma Announces Positive Clinical Update from Ongoing Phase 2 HARMONIC™ Clinical Trial for Never Smokers with Advanced NSCLC, Including an 86% Clinical Benefit Rate in the Initial Patient Cohort

The Phase 2 HARMONIC™ study is designed for never smokers with lung adenocarcinoma with the objective to overcome driver mutation(s) – which are more common in never smokers – that lead to...

Lantern Pharma to Report Second Quarter 2024 Operating & Financial Results on August 8th, 2024 at 4:30 p.m. ET

Webcast to be held Thursday, August 8th, 4:30 p.m. ET, register for the webcast here, or at the link provided below. Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (“AI”) company...

Lantern Pharma Achieves Key Milestone Towards Development of Molecular Diagnostic for use in Oncology Clinical Trials for Patient Selection and Stratification with Drug Candidate LP-184

Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging artificial intelligence (AI) and machine learning to transform the cost, pace, and timeline of oncology drug...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.8-19.27710843374.154.153.25513923.54535325CS
4-0.4358-11.51143747693.78584.7943.25455564.13545392CS
12-1.49-30.78512396694.845.13.25580464.18976518CS
26-4.75-58.64197530868.111.993.251520866.98723351CS
52-1.13-25.22321428574.4811.992.381204606.41090208CS
156-10.59-75.968436154913.9413.942.38702916.44614179CS
260-11.81-77.902374670215.1624.842.38760829.76887238CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
FTCIFTC Solar Inc
$ 0.53
(135.45%)
30.04M
QHQuhuo Ltd
$ 2.48
(86.47%)
25.44M
INMInMed Pharmaceuticals Inc
$ 0.3782
(39.61%)
4.56M
TANHTantech Holdings Ltd
$ 0.1698
(22.69%)
2.28M
PTIXProtagenic Therapeutics Inc
$ 1.23
(19.42%)
306.57k
TBIOTelesis Bio Inc
$ 1.67
(-56.05%)
52.6k
HCTIHealthcare Triangle Inc
$ 0.5003
(-15.48%)
56.51k
FEIMFrequency Electronics Inc
$ 12.15
(-11.51%)
24.12k
MDJHMDJM Ltd
$ 0.9931
(-8.88%)
49.78k
NITON2OFF Inc
$ 0.3142
(-8.50%)
118.38k
FTCIFTC Solar Inc
$ 0.53
(135.45%)
30.04M
QHQuhuo Ltd
$ 2.48
(86.47%)
25.44M
WTOUTime Limited
$ 0.0379
(-5.25%)
12.84M
INMInMed Pharmaceuticals Inc
$ 0.3782
(39.61%)
4.56M
GRABGrab Holdings Ltd
$ 3.37
(0.60%)
4.07M

LTRN Discussion

View Posts
Monksdream Monksdream 1 week ago
LTRN under $5
👍️0
anabu9 anabu9 4 weeks ago
Finally an UP day. 'hope institutions will see this nugget soon
👍️0
FALCON1 FALCON1 1 month ago
https://www.zacks.com/stock/news/2300964/the-zacks-analyst-blog-highlights-danaher-morgan-stanley-pfizer-elite-pharmaceuticals-and-oil-dri
https://www.zacks.com/stock/news/2300922/zacks-initiates-coverage-of-elite-pharmaceuticals-with-outperform-recommendation
👍️0
dinogreeves dinogreeves 4 months ago
Nice drop
🕳️ 1 🪦 1 ⚰️ 1
Monksdream Monksdream 4 months ago
LTRN under $10
👍️0
Monksdream Monksdream 6 months ago
Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?orderBy=percentChange&orderDir=desc
👍️0
dinogreeves dinogreeves 6 months ago
Monk, take a look at ANV*S. Data is due sometime in April, Parkinsons and Alzheimers. They just did a private placement on Friday and another one today to an institutional investor. "Subject to Certain Conditions". Looks like April is go time.
👍️0
dinogreeves dinogreeves 6 months ago
I think we can revisit the high again hopefully this week. Been here since 7.20
🖕🏻 1
spartex spartex 6 months ago
10-K filing, Earnings Webcast, Presentation in link below from LTRN company website


https://ir.lanternpharma.com/news-events/press-releases/detail/150/lantern-pharma-reports-fourth-quarter-fiscal-year-2023
👍️0
Monksdream Monksdream 6 months ago
LTRN new 52 hi
👍️0
dinogreeves dinogreeves 6 months ago
Another very good day today.
👍️0
Monksdream Monksdream 6 months ago
LTRN 10Q due 3/18
👍️0
dinogreeves dinogreeves 6 months ago
Very good move on Friday.
🪦 1 ☠️ 1 ⚰️ 1 ⚱️ 1
dinogreeves dinogreeves 6 months ago
This company will see 3 digit dollars, how soon? All depends on just one science behind their Artificial Intelligence to decode one cancer indication the rest will be history.
👍️0
dinogreeves dinogreeves 6 months ago
This is going to have one heck of a run.
👍️0
Tremors! Tremors! 6 months ago
Will they break 10.00!??
👍️0
Roily23 Roily23 6 months ago
👍️0
Roily23 Roily23 6 months ago
AI is the next .com and AI's application in medicine and pharma will be a game changer.

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. It develops LP-100 for treatment in combination with the class of anticancer agent known as PARP inhibitors. The company also develops LP-300 as a combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; and LP-284, a novel small molecule and DNA damaging agent for the treatment of mantle cell lymphoma and double hit lymphoma. In addition, it offers LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.
👍️0

Your Recent History

Delayed Upgrade Clock